Gossamer Bio
Gossamer Bio's revenue fell 57.7% to $48 million in fiscal 2025. Its operating margin was −352.2%, down from −52.2% a year earlier. Free cash flow was −$171 million. The diluted share count rose 1.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Gossamer Bio does
Gossamer Bio is a drug developer in San Diego with no approved products. Its work centers on one experimental medicine, seralutinib, an inhaled drug for pulmonary arterial hypertension, or PAH: a rare disease in which the small blood vessels of the lungs thicken and narrow, straining the heart. It has also studied the drug for high blood pressure in the lungs linked to lung scarring.
In February 2026 the company reported the main results of its late-stage trial in 390 PAH patients. The drug improved how far patients could walk in six minutes compared with a placebo, but the result missed the trial's preset bar for statistical proof. Gossamer says it plans to discuss the data with the US Food and Drug Administration before deciding whether to apply for approval, and it paused enrollment in a second late-stage trial.
Gossamer develops seralutinib with the drugmaker Chiesi under a 2024 agreement. In the United States the two would share sales efforts, each doing 50% of the work, and Chiesi holds the sole right to sell the drug elsewhere. After the trial results, Gossamer cut about 48% of its staff in March 2026 to save cash. It also has an option to work on a second inhaled PAH drug, RT234, with Respira Therapeutics.
Its biggest risks, as it describes them
- The late-stage trial results may not be enough for the FDA to approve seralutinib or to justify more development.
- Nearly all of its prospects rest on a single experimental drug.
- It has lost money since it began and needs more funding, which could dilute shareholders or force cuts.
- Its debt, including convertible notes, could strain the cash it has for operations.
- It relies on Chiesi and on outside firms to run trials and make the drug.
Income statement
Gossamer Bio lost money in fiscal 2025: a net loss of $170 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 325 | 256 | 296 | 294 | 137 |
| Debt incl. finance leases | 29 | 24 | 12 | 0 | 0 |
| Net debt (negative means net cash) | −296 | −232 | −284 | −294 | −137 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.2x | — | 0.2x | 0.0x | — |
| Interest coverage | −11.1x | −15.8x | −13.6x | −5.2x | −15.5x |
| Current ratio | 8.3x | 5.3x | 5.9x | 6.9x | 2.6x |
| Quick ratio | 8.3x | 5.3x | 5.9x | 6.9x | 2.6x |
Cash flow
Projections
Project Gossamer Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Gossamer Bio reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 8 | 5 of 8 | 0 of 8 |
| Rule of 40 | — | — | −411.2% |
| Altman Z'' | −11.00 | −8.77 | −30.36 |
| Accruals ratio | −7.1% | −16.9% | 0.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 4 of 8 | 5 of 8 | 0 of 8 |
Compare
Put Gossamer Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Gossamer Bio | FY25 | −57.7% | −352.2% | −353.5% | — | — | 0 | |
| Protagonist Therapeutics | FY25 | −89.4% | −343.6% | 121.9% | — | — | — | Compare |
| Septerna | FY25 | 4,174.5% | −148.6% | 238.7% | — | — | — | Compare |
| Protalix BioTherapeutics | FY25 | −1.2% | −10.4% | −25.8% | — | — | — | Compare |
| Fennec Pharmaceuticals | FY25 | −6.1% | −14.1% | — | — | — | — | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | — | — | — | 0 | 0 | 115 | 48 |
| Revenue growth | — | — | — | — | — | — | — | — | −57.7% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 1 | 55 | 143 | 161 | 170 | 171 | 135 | 138 | 174 |
| Operating income | −7 | −149 | −186 | −234 | −216 | −219 | −184 | −60 | −171 |
| Net income | −7 | −147 | −180 | −243 | −234 | −229 | −180 | −56 | −170 |
| Diluted EPS (US$) | −0.74 | −22.59 | −3.29 | −3.55 | −3.13 | −2.71 | −1.18 | −0.25 | −0.75 |
| Diluted shares (millions) | 9 | 6 | 55 | 68 | 75 | 85 | 153 | 226 | 228 |
| Cash flow | |||||||||
| Cash from operations | −6 | −51 | −145 | −176 | −189 | −187 | −159 | −4 | −171 |
| Capital expenditure | — | 4 | 3 | 2 | 2 | 0 | 0 | 0 | 0 |
| Free cash flow | — | −55 | −148 | −178 | −190 | −187 | −159 | −3 | −171 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 31 | 21 | 39 | 32 | 43 | 28 | 21 | 11 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 0 | 229 | 402 | 513 | 325 | 256 | 296 | 294 | 137 |
| Debt incl. finance leases | — | — | 28 | 29 | 29 | 24 | 12 | 0 | 0 |
| Total assets | — | 239 | 427 | 539 | 344 | 272 | 312 | 315 | 172 |
| Total liabilities | — | 21 | 74 | 219 | 222 | 260 | 249 | 286 | 295 |
| Shareholders' equity | −7 | −120 | 352 | 321 | 122 | 12 | 63 | 30 | −123 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | −52.2% | −352.2% |
| Net margin | — | — | — | — | — | — | — | −49.3% | −351.5% |
| Free cash flow margin | — | — | — | — | — | — | — | −3.0% | −353.5% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | −411.2% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −155.2% | −72.3% | −105.8% | −343.5% | −480.5% | −122.5% | — |
| Return on assets | — | — | −54.1% | −50.4% | −53.0% | −74.5% | −61.5% | −18.0% | −69.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |